Factors associated with first-year discontinuation of Implanon in Upper Egypt: clients' and providers' perspectives

被引:18
作者
Aziz, Mirette M. [1 ]
El-Gazzar, Amira F. [1 ]
Elgibaly, Omaima [1 ]
机构
[1] Assiut Univ, Publ Hlth & Community Med, Assiut 71515, Egypt
关键词
CONTRACEPTIVE IMPLANTS; NIGERIA;
D O I
10.1136/bmjsrh-2017-101860
中图分类号
D669 [社会生活与社会问题]; C913 [社会生活与社会问题];
学科分类号
1204 ;
摘要
Background The etonogestrel implant Implanon is a favourable and cost-effective contraceptive method for women in developing countries, and expansion of its use represents a priority for the family planning (FP) programme in Egypt. We studied the factors affecting first-year Implanon discontinuation from clients' and providers' perspectives. Methods We used a mixed quantitative-qualitative methodology. We conducted a household survey of Implanon clients and three focus group discussions with FP physicians and directors. Results We found that 13.5% of Implanon users discontinued its use in the first year. Survival analysis found that clients who had previously used Implanon (HR 0.36, 95% Cl 0.15 to 0.88) and whose husbands had secondary or a higher level of education (HR 0.36, 95% Cl 0.19 to 0.69) were less likely to discontinue Implanon use after the first year, while clients who experienced side effects of Implanon use were more likely to discontinue it (HR 3.6, 95% Cl 1.60 to 8.11). Other causes of discontinuation which emerged in the qualitative analysis were the unjustified advice for Implanon removal by non-gynaecologists, due to unrelated users' complaints, and deficient pre-insertion counselling. Conclusions Implanon has a low first-year discontinuation rate as compared with other contraceptive methods. FP clients should be given sufficient pre-insertion counselling about side effects of Implanon and duration of protection. Physicians should offer Implanon mainly to clients seeking long-term contraception in order to decrease its discontinuation rate and increase its cost effectiveness.
引用
收藏
页码:260 / 266
页数:7
相关论文
共 26 条
  • [1] Adebola OR, 2015, J REPROD CONTRACEPT, V26, P46, DOI [10.7669/j.issn.1001-7844.2015.01.0046, DOI 10.7669/J.ISSN.1001-7844.2015.01.0046]
  • [2] An assessment of the first 3 years' use of Implanon® in Luton
    Agrawal, A
    Robinson, C
    [J]. JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2005, 31 (04) : 310 - 312
  • [3] Aradhya KW., 2007, MED ED RESOURCE AFRI, V30, P3
  • [4] Birhane KA., 2015, IJPSR, V6, P554
  • [5] Blanc AK, 1999, MEASURE EVALUATION T
  • [6] EDHS. El-Zanaty and Associates [ Egypt] and ICF International, 2015, EG DEM HLTH SURV 201
  • [7] Ezegwui H U, 2011, Niger J Med, V20, P448
  • [8] US women's one-year contraceptive use patterns, 2004
    Frost, Jennifer J.
    Singh, Susheela
    Finer, Lawrence B.
    [J]. PERSPECTIVES ON SEXUAL AND REPRODUCTIVE HEALTH, 2007, 39 (01) : 48 - 55
  • [9] Safety and efficacy of Implanon™, a single-rod implantable contraceptive containing etonogestrel
    Funk, S
    Miller, MM
    Mishell, DR
    Archer, DF
    Poindexter, A
    Schmidt, J
    Zampaglione, E
    [J]. CONTRACEPTION, 2005, 71 (05) : 319 - 326
  • [10] Glaser B.G., 1967, Awareness of dying